BriaCell Therapeutics Corp. (BCTX): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of BCTX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No BCTX insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BCTX short interest
Moderate short interest. 9.2% of BCTX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 72%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 807,641 BCTX shares were sold short, 9.2% of the shares outstanding, up 2.3% from the report before. At the average daily volume of 64,791 shares, buying them all back would take about 12.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 807,641 | 9.25% | +2% | 64,791 | 12.5 |
| Oct 15, 2026 | 789,493 | 9.07% | +1% | 55,447 | 14.2 |
| Sep 30, 2026 | 779,096 | 8.96% | -2% | 200,420 | 3.9 |
| Sep 15, 2026 | 792,224 | 9.11% | +9% | 92,530 | 8.6 |
| Aug 31, 2026 | 723,836 | 8.32% | +81% | 967,776 | 1.0 |
| Aug 14, 2026 | 398,913 | 4.59% | -2% | 119,474 | 3.3 |
| Jul 31, 2026 | 408,294 | 4.69% | -9% | 68,628 | 6.0 |
| Jul 15, 2026 | 448,078 | 5.15% | +18% | 241,432 | 1.9 |
| Jun 30, 2026 | 380,150 | 4.37% | +1% | 96,201 | 4.0 |
| Jun 15, 2026 | 377,009 | 4.33% | -57% | 250,931 | 1.5 |
| May 29, 2026 | 867,761 | 11.97% | +85% | 269,245 | 3.2 |
| May 15, 2026 | 470,162 | 6.48% | -0% | 256,138 | 1.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
BriaCell Therapeutics company events
BriaCell Therapeutics filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Jun 26, 2026.
- Jun 26, 2026AnnouncementShared information with investors. Filing
- Jun 3, 2026AgreementBriaCell Therapeutics Corp. entered into a Placement Agency Agreement with ThinkEquity LLC, pursuant to which the Company agreed to issue and sell directly to investors, in a best efforts offering, an aggregate of 1,449,300 common shares of the Company at an offering price of $3.25 per common share. Filing
- Mar 31, 2026AnnouncementShared information with investors. Filing
- Mar 9, 2026VoteReported shareholder vote results. Filing
- Feb 20, 2026AnnouncementBriaCell Therapeutics Corp. announced that it has entered into an asset purchase agreement with its majority-owned subsidiary, BriaPro Therapeutics Corp., pursuant to which BriaPro has agreed to acquire the Company’s exclusive license to develop and commercialize Soluble CD80 as a therapeutic agent… Filing
- Jan 15, 2026AgreementBriaCell Therapeutics Corp. consummated a public offering of 4,327,530 units and 1,039,196 pre-funded units for a purchase price of $5.59 per Common Unit and $5.589 per Pre-funded Unit, resulting in aggregate gross proceeds of approximately $30 million, before deducting placement agent fees and… Filing
- Dec 29, 2025AnnouncementShared information with investors. Filing
- Dec 1, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
BriaCell Therapeutics financials
Famous investors that hold BCTX
1 of the 50 well-known investors we track reported holding BCTX in their latest 13F filing. The largest position is Ken Griffin's, worth $1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 861,329 | $1M | 0.0% | -5% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about BriaCell Therapeutics Corp. (BCTX) stock
Are BCTX insiders buying or selling?
No BCTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in BCTX?
As of Oct 30, 2026, 807,641 BCTX shares were sold short, 9.2% of the shares outstanding, up 2.3% from the report before. At the average daily volume of 64,791 shares, buying them all back would take about 12.5 trading days (days to cover). See the history.
Which famous investors hold BCTX?
1 of the 50 well-known investors we track reported BCTX in their latest 13F filing, including Ken Griffin. The largest position is worth $1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.